Publications by authors named "Sabrina Uhrig"

Claim this Profile
I
Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial.
Milena Beierlein, Lothar Häberle, Naiba Nabieva, Nicolai Maass, Bahriye Aktas, Sabrina Uhrig

Int J Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival in Metastatic Breast Cancer Patients: Real-World Data from 1,000 Patients Treated at the NCT Heidelberg between 2014 and 2022.
Laura L Michel, Manuel Feisst, Verena Thewes, Dirk Jäger, Andreas D Hartkopf, Sabrina Uhrig

Breast Care (Basel)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer.
Laura L Michel, Philipp Ziegler, Philipp Kreis, Andreas D Hartkopf, Markus Wallwiener, Sabrina Uhrig

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence to digital pregnancy care - lessons learned from the SMART start feasibility study.
Katharina M Jaeger, Michael Nissen, Heike Leutheuser, Nina Danzberger, Adriana Titzmann, Sabrina Uhrig

NPJ Digit Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk.
Volkmar Müller, Manuel Hörner, Marc Thill, Maggie Banys-Paluchowski, Sabine Schmatloch, Sabrina Uhrig

Breast· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer - the SERAPHINA study.
Andreas Schneeweiss, Peter A Fasching, Marc Thill, Marion van Mackelenbergh, Frederik Marme, Sabrina Uhrig

J Cancer Res Clin Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Digital Home-Based Health Care Center for Remote Monitoring of Side Effects During Breast Cancer Therapy: Prospective, Single-Arm, Monocentric Feasibility Study.
Hanna Huebner, Lena A Wurmthaler, Chloë Goossens, Mathias Ernst, Alexander Mocker, Sabrina Uhrig

JMIR Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer.
Christina B Walter, Andreas D Hartkopf, Alexander Hein, Peter A Fasching, Hans-Christian Kolberg, Sabrina Uhrig

Breast· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients: mutation frequencies, testing intention, and clinical impact.
Hanna Huebner, Pauline Wimberger, Elena Laakmann, Eugen Ruckhäberle, Matthias Ruebner, Sabrina Uhrig

Precis Clin Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of delayed isolation of peripheral blood mononuclear cells on cell viability and functionality.
Sarah Lehle, Simon Völkl, Katharina Seitz, Chloë Goossens, Julius Emons, Sabrina Uhrig

BMC Immunol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype.
Philipp Ziegler, Andreas D Hartkopf, Markus Wallwiener, Lothar Häberle, Hans-Christian Kolberg, Sabrina Uhrig

BMC Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.
Peter A Fasching, Carolin C Hack, Naiba Nabieva, Nicolai Maass, Bahriye Aktas, Sabrina Uhrig

Eur J Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer.
Peter A Fasching, Chunling Hu, Steven N Hart, Matthias Ruebner, Eric C Polley, Sabrina Uhrig

NPJ Breast Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry.
Andreas D Hartkopf, Christina B Walter, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Sabrina Uhrig

Geburtshilfe Frauenheilkd· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.
Carolin C Hack, Nicolai Maass, Bahriye Aktas, Sherko Kümmel, Christoph Thomssen, Sabrina Uhrig

Geburtshilfe Frauenheilkd· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.
Carolin C Hack, Nicolai Maass, Bahriye Aktas, Sherko Kümmel, Christoph Thomssen, Sabrina Uhrig

Geburtshilfe Frauenheilkd· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041).
Peter A Fasching, Alexander Hein, Hans-Christian Kolberg, Lothar Häberle, Sabrina Uhrig

Eur J Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Return of individual genomic research results within the PRAEGNANT multicenter registry study.
Hanna Huebner, Matthias Ruebner, Christian Kurbacher, Peyman Hadji, Andreas D Hartkopf, Sabrina Uhrig

Breast Cancer Res Treat· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT.
Tobias Engler, Peter A Fasching, Diana Lüftner, Andreas D Hartkopf, Volkmar Müller, Sabrina Uhrig

Geburtshilfe Frauenheilkd· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.
Volkmar Müller, Alexander Hein, Andreas D Hartkopf, Peter A Fasching, Hans-Christian Kolberg, Sabrina Uhrig

Eur J Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations in and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.
Peter A Fasching, Siddhartha Yadav, Chunling Hu, Marius Wunderle, Lothar Häberle, Sabrina Uhrig

J Clin Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine.
Elena Laakmann, Julius Emons, Florin-Andrei Taran, Wolfgang Janni, Sabrina Uhrig

Geburtshilfe Frauenheilkd· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine.
Elena Laakmann, Julius Emons, Florin-Andrei Taran, Wolfgang Janni, Sabrina Uhrig

Geburtshilfe Frauenheilkd· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis